Juniper Pharma Services (JPS), a Contract Development and Manufacturing Organization (CDMO) specializing in the development of challenging small molecules, has announced a significant expansion to its UK-based drug development and clinical trial manufacturing facilities.
The extension provides four additional process development laboratories at its Nottingham site, improving the output and efficiency of its development and clinical manufacturing operations.
Set to be fully operational by summer 2018, the new laboratory space will allow JPS to work with an ever-growing client base to transform poorly soluble and difficult to formulate molecules into successful products. The expansion will ensure that processing and formulation work is scalable, enabling the efficient manufacture of stability and clinical batches.
The expansion demonstrates Juniper Pharma Services’ growth in the drug development arena and its increasing commitment to solving tough formulation challenges. The new facilities, combined with JPS’ long-standing expertise in drug formulation development, is desirable to many pharmaceutical clients and enhances the company’s reputation as a leading CDMO in the UK and globally.
Nikin Patel, president at Juniper Pharma Services, commented, “We are always exploring opportunities to extend our service offerings to meet the evolving requirements of our market and clients. This facility expansion, which has significantly increased Juniper Pharma Services’ capacity, is the latest effort in this Endeavor.”
